Dextromethorphan

US Approved OTC

First approved in 1954

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H25NO
Molecular Weight	271.3972
Optical Activity	( + )
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)C2=C1

InChI

InChIKey=MKXZASYAUGDDCJ-NJAFHUGGSA-N

InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H25NO
Molecular Weight	271.3972
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/2694543 http://www.who.int/medicines/areas/quality_safety/5.1Dextromethorphan_pre-review.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/25420446

Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive for almost 40 years. It has attracted attention due to its anticonvulsant and neuroprotective properties. It is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Dextromethorphan shows high-affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist and acts as a non-competitive channel blocker. It is one of the widely used antitussives and is used to study the involvement of glutamate receptors in neurotoxicity. Dextromethorphan (DM) is a sigma-1 receptor agonist and an uncompetitive NMDA receptor antagonist. The mechanism by which dextromethorphan exerts therapeutic effects in patients with pseudobulbar affect is unknown. Dextromethorphan should not be taken with monoamine oxidase inhibitors due to the potential for serotonin syndrome. Dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan, which is rapidly glucuronidated and unable to cross the blood-brain barrier.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 64 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099	Agonist 2752		205.0 nM [Ki]
Glutamate [NMDA] receptor subunit 3A 21 Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21620_mucinex_lbl.pdf	Primary		Approved 8583	MUCINEX DM Approved Use Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive: temporarily relieves: cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants; the intensity of coughing; the impulse to cough to help you get to sleep Launch Date 2004
Pseudobulbar affect 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26000221	Primary		Approved 8583	NUEDEXTA Approved Use NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. Launch Date 2010

C_max

Value	Dose	Co-administered	Analyte	Population
2.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
599 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
709 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
15.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
95.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
124.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
123.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
68 nM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01361217	30 mg single, oral dose: 30 mg route of administration: oral experiment type: single co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: healthy age: adults sex: food status:
17.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
32 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2898 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	45 mg 2 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
52 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
133.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1049 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
933.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1000.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTRORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342614/	30 mg 2 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: QUINIDINE	QUINIDINE	DEXTROMETHORPHAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
50 mg 4 times / day steady, oral Dose: 50 mg, 4 times / day Route: oral Route: steady Dose: 50 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	unhealthy, 19-52 years Health Status: unhealthy Age Group: 19-52 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8741125	Sources: https://pubmed.ncbi.nlm.nih.gov/8741125
960 mg 1 times / day multiple, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: multiple Dose: 960 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	unhealthy, 19-67 years Health Status: unhealthy Age Group: 19-67 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2529964	Sources: https://pubmed.ncbi.nlm.nih.gov/2529964
120 mg single, oral Recommended Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	healthy, 26.5 years Health Status: healthy Age Group: 26.5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/26294136	Sources: https://pubmed.ncbi.nlm.nih.gov/26294136
900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years Health Status: unknown Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	Other AEs: Ischemic colitis... Other AEs: Ischemic colitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	Other AEs: Lethargy, Ataxia... Other AEs: Lethargy (1 patient) Ataxia (1 patient) Nystagmus (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

AEs

AE	Significance	Dose	Population
Ischemic colitis	1 patient	900 mg single, oral Overdose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/31033494	unknown, 27 years Health Status: unknown Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/31033494
Ataxia	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Lethargy	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593
Nystagmus	1 patient	270 mg single, oral Overdose Dose: 270 mg Route: oral Route: single Dose: 270 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2018593	unknown, 3 years Health Status: unknown Age Group: 3 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/2018593

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP2E1 1060	P-gp 2052	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021879s000lbl.pdf#page=14 Page: 14.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.eurekaselect.com/66423/article/lack-interaction-nmda-receptor-antagonists-dextromethorphan-and-dextrorphan-p	no
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11602530/ Page: 2.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021879Orig1s000OtherR.pdf#page=63 Page: 63.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4470	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4470
ZINC	ZINC000003201907	http://zinc15.docking.org/substances/ZINC000003201907

PubMed

Title	Date	PubMed
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.	2009-04-07	19344034
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice.	2009-04-01	19189960
[Bone anchored hearing aids (BAHA)].	2009-03	19343390
The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.	2009-02-18	19226451
Amyotrophic lateral sclerosis.	2009-02-03	19192301
Characterization of retrieved orthodontic miniscrew implants.	2009-01	19121491
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.	2009-01	19029129
Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice.	2009	19258215
Effects of common antitussive drugs on the hERG potassium channel current.	2008-12	19034038
Effects of repeated cycles of sterilisation on the mechanical characteristics of titanium miniplates for osteosynthesis.	2008-09	18336967
Anti-inflammatory effects of dimemorfan on inflammatory cells and LPS-induced endotoxin shock in mice.	2008-07	18500357
Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening.	2008-07	18420780
Life-threatening dextromethorphan intoxication associated with interaction with amitriptyline in a poor CYP2D6 metabolizer: a single case re-exposure study.	2008-07	18359183
Mechanical aspects of a multidirectional, angular stable osteosynthesis system and comparison with four conventional systems.	2008-04	18346904
Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.	2008-04	18221780
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.	2008-01-08	18281903
Ubiquitous computing for remote cardiac patient monitoring: a survey.	2008	18604301
Prior exposure to uninfected mosquitoes enhances mortality in naturally-transmitted West Nile virus infection.	2007-11-14	18000543
Effect of sodium ozagrel on the activity of rat CYP2D6.	2007-11-14	17651725
Effects of dextromethorphan on dopamine dependent behaviours in rats.	2007-08	17877148
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.	2007-08	17470523
Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain.	2007-07	17573115
In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies.	2007-07	17565714
Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.	2007-07	17333164
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.	2007-06-01	17543114
Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry.	2007-06-01	17267297
[Simultaneous determination of the inhibitory potency of compounds on the activity of five cytochrome P-450 enzymes using a cocktail probe substrates method].	2007-06	17702393
Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.	2007-05-09	17418993
Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study.	2007-04	17488670
Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.	2007-04	17225166
Treatment of the common cold.	2007-02-15	17323712
A placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism.	2007-01	17175572
Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.	2007	18096088
Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure.	2007	17903238
Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.	2007	17461892
Co-administration of dextromethorphan with methamphetamine attenuates methamphetamine-induced rewarding and behavioral sensitization.	2006-09	16865411
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findings.	2006-06-27	16801672
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.	2006-05	16634036
Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan.	2006-04-04	17102908
Cluster formation as a tool for development in Medicon Valley.	2006-02-21	16485399
Dextromethorphan psychosis, dependence and physical withdrawal.	2005-12	16318953
Recombinant production of human microsomal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris.	2005-11	16222729
Side effects of dextromethorphan abuse, a case series.	2005-09	16122622
Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers.	2005-06	15988119
Dextromethorphan-induced delirium and possible methadone interaction.	2005-03	16089243
[Dextromethorphan enhances analgesic activity of propacetamol--experimental study].	2005	17037292
Phenotypical expression of CYP2D6 in amerindians of tepehuano origin from Durango, Mexico.	2005	16416672
Epigenetic silencing of DSC3 is a common event in human breast cancer.	2005	16168112
High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry.	2005	16124035
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist.	1991-03-01	1685312

Patents

Sample Use Guides

In Vivo Use Guide

15-30 mg 3 to 4 times per day (cough) 20-30 mg twice daily (pseudobulbar affect)

Route of Administration: Oral

In Vitro Use Guide

In vitro studies pre- and immature oligodendroglial (OLN-93) cells were subjected to hyperoxic conditions for 48 h after pre-treatment with increasing doses of dextromethorphan.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:45:38 GMT 2025` Edited by `admin` on `Mon Mar 31 17:45:38 GMT 2025`
Record UNII	7355X3ROTS
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

Dextromethorphan

Official Name

English

BA-2666

Preferred Name

English

BA 2666

Common Name

English

DEX

Common Name

English

NSC-751452

Code

English

DEXTROMETHORPHAN [VANDF]

Common Name

English

Dextromethorphan [WHO-DD]

Common Name

English

NODEX

Common Name

English

DEXTROMETHORPHAN [MI]

Common Name

English

D-METHORPHAN

Common Name

English

(+)-DEXTROMETHORPHAN

Common Name

English

DXM

Common Name

English

DEXTROMETHORPHAN [USP MONOGRAPH]

Common Name

English

DEXTROMETHORPHAN [MART.]

Common Name

English

MORPHINAN, 3-METHOXY-17-METHYL-, (9.ALPHA.,13.ALPHA.,14.ALPHA.)-

Common Name

English

3-Methoxy-17-methyl-9?,13?,14?-morphinan

Common Name

English

DEXTROMETHORPHAN [HSDB]

Common Name

English

dextromethorphan [INN]

Common Name

English

DEXTROMETHORPHAN [USP-RS]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000181821